BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22143060)

  • 1. Front-line therapy for chronic lymphocytic leukemia.
    Desai S; Pinilla-Ibarz J
    Cancer Control; 2012 Jan; 19(1):26-36. PubMed ID: 22143060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia: a clinical review.
    Nabhan C; Rosen ST
    JAMA; 2014 Dec; 312(21):2265-76. PubMed ID: 25461996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Abbott BL
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia.
    Byrd JC; Stilgenbauer S; Flinn IW
    Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.
    Wilhelm K; Yang D
    J Oncol Pharm Pract; 2011 Jun; 17(2):91-103. PubMed ID: 20085962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
    Nabhan C; Dyer MJ; Rosen ST
    Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody combinations in CLL: evolving strategies.
    Faderl S; O'Brien S; Keating MJ
    Best Pract Res Clin Haematol; 2006; 19(4):781-93. PubMed ID: 16997183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events.
    Chanan-Khan A; Kipps T; Stilgenbauer S
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):suppl 1-15. PubMed ID: 21192630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Lin TS
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist.
    Pinilla-Ibarz J; Emole J
    Cancer Control; 2015 Oct; 22(4 Suppl):7-16. PubMed ID: 26618341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approach to diagnosis and management of chronic lymphocytic leukemia.
    Shanafelt TD; Call TG
    Mayo Clin Proc; 2004 Mar; 79(3):388-98. PubMed ID: 15008611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
    Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.